Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
78
-
Total 13F shares, excl. options
-
28M
-
Shares change
-
-361K
-
Total reported value, excl. options
-
$430M
-
Value change
-
-$1.91M
-
Number of buys
-
31
-
Number of sells
-
-27
-
Price
-
$15.38
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q4 2020
85 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q4 2020.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 78 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28M shares
of 77.3M outstanding shares and own 36.2% of the company stock.
Largest 10 shareholders include BVF INC/IL (3.5M shares), Avoro Capital Advisors LLC (2.8M shares), FMR LLC (2.63M shares), ORBIMED ADVISORS LLC (2.5M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.45M shares), Capital International Investors (1.06M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.03M shares), NEA Management Company, LLC (992K shares), Capital World Investors (964K shares), and Bank of New York Mellon Corp (949K shares).
This table shows the top 78 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.